AIDS Funding Shifts to the Laboratory

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

WASHINGTON--William Paul, MD, director of the NIH Office of AIDS Research, has announced that AIDS funding will begin to shift away from clinical research toward investigator-initiated laboratory research. He said that continuation of past policies will result in only "slow, fitful progress."

WASHINGTON--William Paul, MD, director of the NIH Office of AIDSResearch, has announced that AIDS funding will begin to shiftaway from clinical research toward investigator-initiated laboratoryresearch. He said that continuation of past policies will resultin only "slow, fitful progress."

Dr. Paul appointed a new task force, chaired by Arnold Levine,a Princeton University molecular biologist, to determine researchpriorities.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content